Raises another $300 million in convertible debt

Analysis

The near-term pain is clear: the Q1 loss, the convertible raise and the margin squeeze from the shift to branded drugs add up to three negatives at once. Medium-term returns depend on the Eucalyptus closing and a ramp-up in international revenue. The key tests are the Q2 results (can subscription growth accelerate to 100,000+ new weight-loss users a month?) and the outcome of the FDA's peptide review on 23 Jul.

Investment implications

ROCE remains under pressure, and the EV denominator is inflating. But management is alert to dilution (the capped call) and is willing to add leverage for an acquisition in adverse conditions, which points to confidence in faster growth in H2. Positioning has to wait for Q2 confirmation.

Key facts

• Offering of $300 million of convertible senior notes due 2032
• A further $45 million over-allotment option for the underwriters
• Proceeds will fund the Eucalyptus acquisition (up to $1.15 billion, expected to close mid-year), international expansion (Australia, Japan, the UK, Germany and Canada), technology and AI investment, and a capped call to hedge dilution
• With the existing $973 million of convertible bonds, total convertible debt rises to about $1.27 billion
• The last convertible raise pushed ROCE down from 18% to 6%, and this one adds to the pressure
• Management has paired the deal with a capped call transaction to limit equity dilution